• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Antifungal susceptibility testing of amphotericin B – problems detected with several commercially available products

EUCAST has so far not defined breakpoints for C. auris, due to the lack of clinical outcome data and the high degree of clonality of this species. Thus, there is currently insufficient evidence to set breakpoints, but EUCAST are aware of other provisional cut-offs which are being used elsewhere, and…

Get to know more

TSU and TRI consultation finalised

Proposed revision of breakpoints for trimethoprim-sulfamethoxazole and trimethoprim. Public consultation 2025-05-07 - 2025-06-18. As a final result of each consultation, the comments obtained and the EUCAST Steering Committee rersponses are made public on the website. These are public comments and…

Get to know more

EUCAST Workshop, ESCMID Global, Saturday 12 April, 8.30 - 11:30 CEST.

Chairs: Alasdair MacGowan (Bristol, United Kingdom), Marlene Amara (Versailles, France) EUCAST update, Sören G. Gatermann (Bochum, Germany) Setting clinical breakpoints, assessing evidence, Anouk Muller (The Hague, Netherlands) Benzylpenicillin susceptibility testing of S. pneumoniae by disk…

Get to know more

Publications and Presentations

Publications by EUCAST in peer-reviewed journals 2025 2024 2023 2022 2021 2020 Archive Aminoglycoside breakpoints – the EUCAST approach and what this means for the clinician. C. Giske et al., Clin. Microbiol. Inf. 2025. Go to publication Rationale for contemporary antimicrobial treatment of…

Get to know more

Industry

Information for pharmaceutical companies intending to bring new antimicrobial drugs to EUCAST for breakpoints The development of clinical breakpoints for new agents requires agreement and acceptance of the data generated in support of decisions on clinical breakpoints, wild type MIC distributions,…

Get to know more

EUCAST calibration and validation graphs updated

Calibration and validation graphs related to breakpoint table v 11.0 (2021) updated 1 July, 2021.New for 2021, apart from introducing revised and new breakpoints for relevant agents and species,are graphs for Achromobacterxylosoxidans , Bacillus spp., Cefiderocol,Ceftolozane-tazobactam for H.…

Get to know more

ECOFFs – the why, the how and the don´ts of EUCAST epidemiological cutoff values.

Identifying the MIC wild type distribution and its delineation of species targeted for receiving antimicrobial agent breakpoints is an important first step for determining clinical breakpoints. Having the main responsibility in EUCAST for characterizing the wild-type distributions and the setting of…

Get to know more

EUCAST - Home

The European Committee on Antimicrobial Susceptibility Testing - EUCAST EUCAST is a scientific committee formed in 1997 and is jointly organized by ESCMID , ECDC and European national breakpoint committees. EUCAST develops antimicrobial susceptibility testing methodology, interpretative criteria and…

Get to know more

RAST FAQ

RAST FAQ Inoculation of agar plates 1. Which is the easiest way to transfer blood from the positive blood culture bottle to the agar plate? Blood can be transferred to the agar plate either by a pipette (after first having transferred blood to an empty tube) or by applying drops on the plate from…

Get to know more

EUCAST Statutes

EUCAST Statutes EUCAST Statutes outlines the objectives, membership structure, consultation and decision process, breakpoint setting for new agents, meetings, publication policy, declarations of interests and funding of EUCAST. The statutes were originally published in November 1999 and have been…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here